Netherlands · 
What does Aglaia Oncology Fund invest in?
Aglaia Oncology Fund invests most often at Series B and Series C (100% of the rounds on record), in sectors such as Oncology, Drug Development and Biotech.
Aglaia Oncology Fund highlights
- 01
2 rounds on record
- 02
Mostly Series B and Series C: 100% of its rounds
What they do
Aglaia is an oncology specialist investor which selects and matures early-stage breakthrough inventions that have the potential to transform cancer prevention, diagnosis and therapy.From their own website
- Type
- VC firm (from a list, unverified)
- Cheque size
- Not stated
- Stages
- Pre-seedSeedSeries A
- Sectors
- OncologyDrug DevelopmentBiotech
- Based in
- Bilthoven, Netherlands
- Cold pitches
- Not accepted
The record
Every round we can evidence, newest first2 appearances
- 2018
1 round
- Apr
- 2015
1 round
- Apr
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
The team
We hold 8 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
What they claim to have backed
From their own portfolio page (on their website)
4 of 9 we have independently watched raise
Cristal Therapeutics -Merus - BispecificMimetas - AnSapreme Technologies -ISA Pharmaceuticals -Inthera Bioscience -Modra - SwitchingORCA Therapeutics -Syntarga - Antibody
Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.